Professor of Oncology
Education and Experience
- University of Texas Medical School at Houston (Houston TX)/ (1986)
- University of Pennsylvania Health System School of Medicine (Philadelphia PA)/ Urology (1992)
- Johns Hopkins University School of Medicine (Baltimore MD)/ Urology (1994)
- Urology, American Board of Urology (2005)
- Bladder Cancer Reseach Center
- Bladder Cancer
- Lower Urinary Tract Reconstruction
- Prostate Cancer
- Urological Oncology
- Urology / Urologic Surgery
- Urology, Adult
Dr. Schoenbergs research group is focused on translational research in the area of urothelial malignancy. Major current work centers on evaluation of diagnostic technologies for bladder cancer as well as novel therapeutic agent evaluation within the context of approved clinical trials. The group has an extensive network of research interactions with investigators at peer institutions. A unique area of expertise within the research group is cancer monitoring in the occupationally exposed. The group has previously conducted large-scale monitoring of benzidine and o-toluidine exposed individuals. In addition, the group has experience working with individuals exposed to hormone disrupters (pesticides) and has previously monitored workers exposed to chlordimeform. The Bladder Cancer Research Center also manages the institutional bladder cancer database in collaboration with the Department of Pathology. The group is supported by extramural funding through the Early Detection Research Network of the NCI, project-specific funding from industry collaborators and philanthropy.
1. Novara G, Svatek RS, Karakiewicz PI, Skinner E, Ficarra V, Fradet Y, Lotan Y, Isbarn H, Capitanio U, Bastian PJ, Kassouf W, Fritsche HM, Izawa JI, Tilki D, Dinney CP, Lerner SP, Schoenberg M, Volkmer BG, Sagalowsky AI, Shariat SF. Soft tissue surgical margin status is a powerful predictor of outcomes after radical cystectomy: a multicenter study of more than 4,400 patients. J Urol. 2010 Jun;183(6):2165-70
2. Tilki D, Reich O, Svatek RS, Karakiewicz PI, Kassouf W, Novara G, Ficarra V, Chade DC, Fritsche HM, Gerwens N, Izawa JI, Lerner SP, Schoenberg M, Stief CG, Skinner E, Lotan Y, Sagalowsky AI, Shariat SF. Characteristics and outcomes of patients with clinical carcinoma in situ only treated with radical cystectomy: an international study of 243 patients. J Urol. 2010 May;183(5):1757-63. Epub 2010 Mar 17.
3. Shariat SF, Svatek RS, Tilki D, Skinner E, Karakiewicz PI, Capitanio U, Bastian PJ, Volkmer BG, Kassouf W, Novara G, Fritsche HM, Izawa JI, Ficarra V, Lerner SP, Sagalowsky AI, Schoenberg MP, Kamat AM, Dinney CP, Lotan Y, Marberger MJ, Fradet Y. International validation of the prognostic value of lymphovascular invasion in patients treated with radical cystectomy. BJU Int. 2010 May;105(10):1402-12. Epub 2010 Feb 2.
4. Ploeg M, Aben KK, Hulsbergen-van de Kaa CA, Schoenberg MP, Witjes JA, Kiemeney LA. Clinical epidemiology of nonurothelial bladder cancer: analysis of the Netherlands Cancer Registry. J Urol. 2010 Mar;183(3):915-20. Epub 2010 Jan 18.
5. Guzzo TJ, McNeil BK, Bivalacqua TJ, Elliott DJ, Sokoll LJ, Schoenberg MP. The presence of circulating tumor cells does not predict extravesical disease in bladder cancer patients prior to radical cystectomy. Urol Oncol. . [Epub ahead of print]
6. Tilki D, Svatek RS, Karakiewicz PI, Isbarn H, Reich O, Kassouf W, Fradet Y, Novara G, Fritsche HM, Bastian PJ, Izawa JI, Stief CG, Ficarra V, Lerner SP, Schoenberg M, Dinney CP, Skinner E, Lotan Y, Sagalowsky AI, Shariat SF. Characteristics and outcomes of patients with pT4 urothelial carcinoma at radical cystectomy: a retrospective international study of 583 patients. J Urol. 2010 Jan;183(1):87-93. Epub .
7. Fritsche HM, Burger M, Svatek RS, Jeldres C, Karakiewicz PI, Novara G, Skinner E, Denzinger S, Fradet Y, Isbarn H, Bastian PJ, Volkmer BG, Montorsi F, Kassouf W, Tilki D, Otto W, Capitanio U, Izawa JI, Ficarra V, Lerner S, Sagalowsky AI, Schoenberg M, Kamat A, Dinney CP, Lotan Y, Shariat SF. Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort. Eur Urol. 2010 Feb;57(2):300-9. Epub 2009 Sep 12.
8. Guzzo TJ, Magheli A, Bivalacqua TJ, Nielsen ME, Attenello FJ, Schoenberg MP, Gonzalgo ML. Pathological upstaging during radical cystectomy is associated with worse recurrence-free survival in patients with bacillus Calmette-Guerin-refractory bladder cancer. Urology. 2009 Dec;74(6):1276-80. Epub 2009 Sep 16.
9. Isbarn H, Karakiewicz PI, Shariat SF, Capitanio U, Palapattu GS, Sagalowsky AI, Lotan Y, Schoenberg MP, Amiel GE, Lerner SP, Sonpavde G. Residual pathological stage at radical cystectomy significantly impacts outcomes for initial T2N0 bladder cancer. J Urol. 2009 Aug;182(2):459-65; discussion 465. Epub 2009 Jun 13.
10. Capitanio U, Suardi N, Shariat SF, Lotan Y, Palapattu GS, Bastian PJ, Gupta A, Vazina A, Schoenberg M, Lerner SP, Sagalowsky AI, Karakiewicz PI. Assessing the minimum number of lymph nodes needed at radical cystectomy in patients with bladder cancer. BJU Int. 2009 May;103(10):1359-62. Epub 2008 Dec 8.
- Bladder Cancer
- Bladder Cancer Diagnostics and Therapeutics